Axe Compute Inc. (AGPU) announced it has completed the sale of its wholly-owned subsidiary, Helomics Corporation, to DataMeds AI, Inc. (NASDAQ: MEDS). The divestiture finalizes Axe Compute's strategic transition into a pure-play neocloud GPU-as-a-Service company, removing the last operating business from its former identity as Predictive Oncology Inc.
Key Details
- Transaction Date: The Stock Purchase Agreement was executed and the transaction closed on September 11, 2026.
- Purchase Price: Consideration consisted of 636,328 shares of DataMeds common stock (representing 19.99% of pre-closing outstanding shares) and a convertible promissory note with a principal amount of $1,363,672.
- Note & Share Terms: The convertible note has a conversion price of $1.00 per share. The shares and any securities converted from the note are subject to a 12-month lock-up period.
- Strategic Impact: The sale completes AGPU's strategic pivot to focus exclusively on its AI infrastructure and GPU-as-a-Service business.